<div id="readability-page-1"><div><p><span>Hannah Brendan Chief Operating Officer of Quince Therapeutics Inc [QNCX] filed a Form 4 on December 8, 2025 with the Securities and Exchange Commission disclosing the following changes in ownership:</span></p><div><table><tbody><tr><td><span>Date</span></td><td><span>12/5/25</span></td></tr><tr><td><span>Transaction</span></td><td><span>Exercise(1)</span></td></tr><tr><td><span>Shares</span></td><td><span>27,551</span></td></tr><tr><td><span>Price</span></td><td><span>$0.91</span></td></tr><tr><td><span>Value</span></td><td><span>$25,014</span></td></tr></tbody></table></div><p><span>Ending Holdings: 361,827 - Direct</span></p><div><table><tbody><tr><td><span>(1)</span></td><td><span>25,280 shares exercised 7.2 years before expiration date.</span></td></tr><tr><td><span> </span></td><td><span>2,271 shares exercised 6.5 years before expiration date.</span></td></tr></tbody></table></div><p><span>For a free trial, or to learn more about our insider trading analysis and data services, please visit http://www.washingtonservice.com or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.</span></p><p><span>Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data.</span></p><span> </span></div></div>

QNCX

<p>Hannah Brendan, COO of Quince Therapeutics Inc, disclosed a change in ownership by filing a Form 4 with the SEC. On December 5, 2025, she exercised 27,551 shares at $0.91 each, totaling $25,014. Her ending holdings are 361,827 shares. The transaction involved exercising shares 7.2 and 6.5 years before their expiration dates.</p>

COO Hannah Acquires 27,551 Of Quince Therapeutics Inc [QNCX]